Immunovant (IMVT) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.41

Estimate

-$0.72

Surprise

+43.7%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Immunovant (IMVT) reported a narrower loss than forecast — adjusted EPS of -$0.41 against the -$0.72 estimate (a 43.7% beat on a still-unprofitable quarter).

• Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33 — benzinga, 2026-11-10
• Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47 — benzinga, 2026-11-10
• Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study — benzinga, 2026-11-09

TrendMatrix currently rates IMVT Sell at 5.2/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +43.7% surprise compares with a +12.0% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$35.39

Price target

$43.99

Stop

$32.91

Upside to target

+24.3%

Reward-to-risk

1.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$7.26B

P/E (fwd)

-12.8

52-week range

$21.43–$45.42

Off 52-week high

22.1%

RSI (14)

74

Volume vs avg

0.24×

Score today

5.2/10